Abbott Laboratories ABT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Abbott Laboratories (ABT) Business Model and Operations Summary
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Key Insights
Abbott Laboratories (ABT) Core Market Data and Business Metrics
Latest Closing Price
$131.69Market Cap
$228.35 BillionPrice-Earnings Ratio
17.24Total Outstanding Shares
1.73 Billion SharesTotal Employees
114,000Dividend
$0.59 Per Share QuarterlyIPO Date
April 19, 1949SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
100 Abbott Park Road, Abbott Park, IL, 60064-3500
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-5.40 Billion |
| Net Cash Flow, Continuing | $816 Million |
| Net Cash Flow From Financing Activities | $-5.40 Billion |
| Net Cash Flow | $816 Million |
| Net Cash Flow From Investing Activities | $-2.34 Billion |
| Net Cash Flow From Operating Activities, Continuing | $8.56 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Costs And Expenses | $35.13 Billion |
| Cost Of Revenue | $18.71 Billion |
| Research and Development | $2.84 Billion |
| Operating Expenses | $16.42 Billion |
| Diluted Average Shares | $1.75 Billion |
| Basic Earnings Per Share | $7.67 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-67 Million |
| Comprehensive Income/Loss | $13.34 Billion |
| Other Comprehensive Income/Loss | $13.34 Billion |
| Comprehensive Income/Loss Attributable To Parent | $13.34 Billion |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $12.46 Billion |
| Noncurrent Assets | $57.76 Billion |
| Other Current Assets | $17.46 Billion |
| Fixed Assets | $10.66 Billion |
| Equity Attributable To Noncontrolling Interest | $237 Million |
| Equity Attributable To Parent | $47.66 Billion |
Historical Dividends
Current dividend: $0.59 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Feb 21, 2025 | May 15, 2025 | Apr 15, 2025 | $0.59 | Quarterly |
| Dec 13, 2024 | Feb 14, 2025 | Jan 15, 2025 | $0.59 | Quarterly |
| Sep 19, 2024 | Nov 15, 2024 | Oct 15, 2024 | $0.55 | Quarterly |
| Jun 14, 2024 | Aug 15, 2024 | Jul 15, 2024 | $0.55 | Quarterly |
| Feb 16, 2024 | May 15, 2024 | Apr 15, 2024 | $0.55 | Quarterly |
| Dec 15, 2023 | Feb 15, 2024 | Jan 12, 2024 | $0.55 | Quarterly |